Clinical trial announced
Marinova is pleased to announce it is conducting a clinical trial investigating the therapeutic potential of its fucoidan compounds in prostate health.
Benign prostatic hyperplasia (BPH), or prostate enlargement, is a significant health issue for men across the globe. The condition becomes increasingly prevalent with age, and while it is typically non-life threatening, it can cause bothersome symptoms including difficulty passing urine and an increase in the frequency of urination. BPH may also lead to bladder, urinary tract or kidney problems.
The company has previously explored the potential of its high purity seaweed extracts to support prostate health with extremely promising results. A 2024 study found that Undaria pinnatifida fucoidan produced by Marinova significantly reduced testosterone-induced BPH symptoms in an animal model. Fucoidan supplementation resulted in significant reductions in prostate weight, prostate index, testosterone, dihydrotestosterone and prostate specific antigen levels in rats, compared to a control group.
Research Scientist at Marinova, Dr Barbara Wimmer, explained. "Following the very encouraging results from our initial study we have now progressed to clinical research into BPH. The study is utilising the same extract - a high purity, certified organic fucoidan derived from the seaweed Undaria pinnatifida. We hope to be in a position to share the results of this study early in 2026. As the search for natural bioactive compounds to support men’s health intensifies, they will inevitably be of interest to the global research community.”